Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid | Zendy

Michael R. Law | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid

Author(s) -

Michael R. Law

Publication year - 2009

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinternmed.2009.320

Subject(s) - pharmacy , medicaid , clopidogrel , business , direct to consumer advertising , confidence interval , medicine , quarter (canadian coin) , advertising , family medicine , medical prescription , aspirin , economics , health care , nursing , archaeology , history , economic growth

Direct-to-consumer advertising (DTCA) is assumed to be a major driver of rising pharmaceutical costs. Yet, research on how it affects costs is limited. Therefore, we studied clopidogrel, a commonly used and heavily marketed antiplatelet agent, which was first sold in 1998 and first direct-to-consumer advertised in 2001.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research